This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Kenneth H. Rand, MD; Thomas C. Merigan, MD

JAMA. 1978;240(22):2470-2471.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Cytomegalovirus (CMV) infection has long been known to follow renal and cardiac transplantation, with infection rates ranging from 38% to 96%.^1-3 While most patients excrete the virus in the urine or in the throat without symptoms, others suffer a relatively severe febrile illness in the first two to three months after transplantation. Additional patients who ostensibly died of bacterial, fungal, or pneumocystis pneumonia were also found to have CMV in lung tissue at postmortem examination. Thus, it was believed that CMV was a near universal accompaniment of transplantation that was generally benign but that occasionally produced a dramatic and occasionally fatal syndrome of pneumonitis, hepatitis, and leukopenia with or without atypical lymphocytosis.

Now, Chatterjee et al (p 2446) present data suggesting that in renal transplant patients, it is not infection with CMV per se that is important but whether this infection is primary or a reactivation of a latent . . . [Full Text PDF of this Article]

Author Affiliations
University of Florida Gainesville; Stanford University Stanford, Calif

Footnotes
Address editorial communications to the Editor, 535 N Dearborn St, Chicago, IL 60610.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?